Pharmacogenomics and Therapeutic Drug Monitoring in Mental Health

By MCL Education • September 25, 2020

Share this:

Expires September 25, 2022

Presentation

Video length: 39 minutes

Overview

In this month's "Virtual Lecture," Ann Moyer, M.D., Ph.D., describes how pharmacogenomics and therapeutic drug monitoring tools aid medical providers in selecting drugs and doses to maximize efficacy while minimizing toxicity for mental illnesses, including depression.

Objectives

Upon completion of this program, participants should be able to:

• Describe scenarios when pharmacogenomics or drug monitoring testing may be useful.
• Recognize the importance of using the results along with the overall clinical picture of the patient.
• Understand the limitations of pharmacogenomics and drug monitoring tests.

Intended Audience

This program is appropriate for clinicians, pathologists, medical technologists, nurses, pharmacists, and other allied health staff.

Presenter

Ann Moyer, M.D., Ph.D.
Associate Professor of Laboratory Medicine and Pathology,
Assistant Professor of Pharmacology
Department of Laboratory Genetics and Genomics
Mayo Clinic, Rochester, Minnesota

Credit

The following types of credit are offered for this program:

ASCLS P.A.C.E.^®

Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.^® program. This program has been approved for a maximum of 0.5 P.A.C.E.^® contact hours.

To obtain credit:

1. Watch the video.
2. Complete the post-test and evaluation that launches immediately following the video.
3. Generate and print your certificate(s).

Level of instruction for this program is basic.

Faculty Disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

Questions?

Contact us: mcleducation@mayo.edu

MCL Education

This post was developed by our Education and Technical Publications Team.